Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of a cefoxitin-inducible beta-lactamase in a case of breakthrough bacteremia.

Literature DB >> 6968320

Role of a cefoxitin-inducible beta-lactamase in a case of breakthrough bacteremia.

Abstract

Development of resistance during therapy with cefamandole contributes to treatment failure. A simple cefoxitin disk test was recently described which detects a cefamandole-active inducible beta-lactamase not otherwise detectable with cefamandole as the inducer. A case of breakthrough Enterobacter bacteremia due to selection of a resistant subpopulation is reported in an immunocompromised patient. The use of this simple disk test in selected clinical cases is advocated.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1980 PMID： 6968320 PMCID： PMC273627 DOI： 10.1128/jcm.12.4.517-520.1980

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

14 in total

1. Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice.

Authors: R V Goering; C C Sanders; W Sanders
Journal: J Antibiot (Tokyo) Date: 1978-04 Impact factor: 2.649

2. Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors: C M Findell; J C Sherris
Journal: Antimicrob Agents Chemother Date: 1976-06 Impact factor: 5.191

3. Gram-negative bacteremia of long duration. Clinical study of 29 patients.

Authors: M C McHenry; T L Gavan; W A Hawk; R A Van Ommen; C A Ma
Journal: Cleve Clin Q Date: 1973

4. Persistent gram-negative bacteremia. Observations in twenty patients.

Authors: J A Harris; C G Cobbs
Journal: Am J Surg Date: 1973-06 Impact factor: 2.565

5. Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.

Authors: R L Perkins; R J Fass; J F Warner; R B Prior; T M File; R R Tight; W G Gardner; D E Ruiz; T G Slama
Journal: J Infect Dis Date: 1978-05 Impact factor: 5.226

6. Efficacy and safety of cefamandole plus either gentamicin or tobramycin in therapy of severe gram-negative bacterial infections.

Authors: L O Gentry
Journal: J Infect Dis Date: 1978-05 Impact factor: 5.226

7. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia.

Authors: E T Anderson; L S Young; W L Hewitt
Journal: Am J Med Date: 1976-10 Impact factor: 4.965

8. Carbenicillin plus cefamandole in the treatment of infections in patients with cancer.

Authors: G P Bodey; S Ketchel; V Rodriguez
Journal: J Infect Dis Date: 1978-05 Impact factor: 5.226

9. Cefamandole in the treatment of infections due to Enterobacter and indole-positive Proteus.

Authors: L R Levine; E McCain
Journal: J Infect Dis Date: 1978-05 Impact factor: 5.226

10. Substrate inhibition of beta-lactamases, a method for predicting enzymatic stability of cephalosporins.

Authors: D F Mahoney; G A Koppel; J R Turner
Journal: Antimicrob Agents Chemother Date: 1976-09 Impact factor: 5.191

13 in total

1. Epidemiological typing of Enterobacter aerogenes.

Authors: M A Gaston; M A Strickland; B A Ayling-Smith; T L Pitt
Journal: J Clin Microbiol Date: 1989-03 Impact factor: 5.948

2. In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.

Authors: T Gootz; J Retsema; A Girard; E Hamanaka; M Anderson; S Sokolowski
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

3. What do beta-lactamases mean for clinical efficacy?

Authors: H C Neu
Journal: Infection Date: 1983 Impact factor: 3.553

4. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.

Authors: A S Bayer; P Lindsay; J Yih; L Hirano; D Lee; I K Blomquist
Journal: Antimicrob Agents Chemother Date: 1986-10 Impact factor: 5.191